Quick answer: Standard cholesterol panels miss the most dangerous cardiovascular risk factors. ApoB — the protein on every atherogenic lipoprotein particle — is a superior predictor of cardiovascular events compared to LDL-C (Sniderman 2019, JAMA Cardiology). Lipoprotein(a) is an independent genetic cardiovascular risk factor present in 20% of people that statins do not reduce. TMAO (trimethylamine N-oxide), produced by gut bacteria from dietary carnitine and choline, is a direct driver of atherosclerosis that statins also don’t address. And 50% of heart attacks occur in people with “normal” LDL. Functional cardiology deploys the biomarker testing and therapeutic toolkit that standard preventive cardiology is only beginning to adopt.
Why LDL Cholesterol Is an Incomplete Cardiovascular Risk Marker
LDL cholesterol (LDL-C) is a concentration measure — it reflects the total cholesterol contained within LDL particles, not the number of particles. Two people can have identical LDL-C values with dramatically different cardiovascular risk depending on LDL particle size and count. Small, dense LDL particles carry less cholesterol per particle but penetrate the arterial endothelium far more easily than large, buoyant LDL — so a person with 120 mg/dL LDL-C from 2,000 small dense particles has much higher risk than a person with 120 mg/dL from 800 large particles.
The clinical consequence: standard LDL-C fails to identify a substantial portion of high-risk individuals. The MESA study (Mora et al., 2007, JACC) found that approximately 46% of cardiovascular events occurred in individuals classified as “low risk” by standard lipid profiles. The European Atherosclerosis Society (2022) and American College of Cardiology now recommend ApoB as the preferred lipid risk marker based on consistent superiority in outcome prediction studies.
ApoB: The Gold Standard Cardiovascular Lipid Marker
ApoB (apolipoprotein B-100) is the structural protein present on every atherogenic lipoprotein particle — VLDL, IDL, LDL, and Lp(a). Since each atherogenic particle contains exactly one ApoB molecule, serum ApoB concentration directly measures the number of atherogenic particles in circulation.
The causal evidence for ApoB: Mendelian randomization studies — using genetic variants affecting ApoB as natural experiments — consistently demonstrate that lower lifetime ApoB exposure is causally associated with lower cardiovascular events with a log-linear relationship, regardless of the mechanism by which ApoB is lowered. Ference et al. (2019, JAMA) analyzed 438,952 participants in 49 studies and found each 1 mmol/L reduction in ApoB was associated with 54% lower risk of coronary heart disease — more than any other lipid marker.
ApoB targets: General population without cardiovascular disease or diabetes: <100 mg/dL. High-risk individuals (diabetes, hypertension, smoking, family history): <80 mg/dL. Very high risk (prior MACE or established atherosclerosis): <70 mg/dL. These targets are stricter than most laboratories’ reference ranges — an ApoB of 90 mg/dL is within the lab “normal range” but represents significantly elevated cardiovascular risk by current European Society of Cardiology guidelines.
ApoB determinants and interventions: ApoB is reduced by: dietary saturated fat reduction (reduces VLDL and LDL production); statins (reduce hepatic cholesterol synthesis → upregulate LDL receptor → increase LDL clearance → reduce circulating ApoB 30–50%); ezetimibe (reduces intestinal cholesterol absorption, additive 15–20% ApoB reduction); PCSK9 inhibitors (evolocumab, alirocumab — reduce ApoB 50–60% on top of statins, with demonstrated MACE reduction in FOURIER and ODYSSEY OUTCOMES trials); bempedoic acid (ATP-citrate lyase inhibitor, reduces LDL-C/ApoB 18–25% for statin-intolerant patients); and dietary fiber (particularly beta-glucan and psyllium, which reduce hepatic LDL receptor downregulation and bile acid reabsorption).
Lipoprotein(a): The Genetic Cardiovascular Time Bomb
Lipoprotein(a) — Lp(a) — is an LDL particle with an additional apolipoprotein(a) attached to ApoB via a disulfide bond. The apolipoprotein(a) component contains repeating kringle IV domains that structurally mimic plasminogen — the endogenous clot-dissolving protein. This structural mimicry means Lp(a) simultaneously promotes atherosclerosis (like LDL) and thrombosis (by competitively inhibiting plasminogen binding and clot dissolution).
Lp(a) levels are 80–90% genetically determined by LPA gene polymorphisms encoding kringle IV repeat number. Lifestyle changes, statins, low-fat diets, exercise, and weight loss minimally affect Lp(a). This is not a lifestyle problem — it is a genetic cardiovascular risk that requires specific pharmacological targeting.
Population data: approximately 20% of the global population has Lp(a) above 50 mg/dL (the threshold consistently associated with elevated cardiovascular risk). The Copenhagen City Heart Study (Kamstrup et al., 2008, JAMA) found that individuals with Lp(a) above 95th percentile had 3.6-fold higher risk of MI and 1.9-fold higher risk of ischemic stroke compared to those below the median. Lp(a) risk is independent of LDL, HDL, triglycerides, and blood pressure.
Current and emerging Lp(a)-specific therapies: Niacin (extended-release) reduces Lp(a) 20–30% and was the only available treatment for decades, though the AIM-HIGH and HPS2-THRIVE trials failed to show cardiovascular benefit from niacin on top of statins — a complex finding being re-evaluated in the context of Lp(a)-targeted patient selection. Pelacarsen (Novartis), an RNA-targeted therapy (ASO — antisense oligonucleotide), reduces Lp(a) 80% in phase III trials — the Lp(a) HORIZON trial (>7,000 participants) is testing cardiovascular outcome reduction. Olpasiran (Amgen siRNA) achieves >90% Lp(a) reduction in phase II — phase III outcomes trials planned. PCSK9 inhibitors reduce Lp(a) 20–25% as a secondary effect. These pipeline drugs represent the first precision pharmacotherapy for a major genetic cardiovascular risk factor.
The clinical implication: every patient with unexplained premature cardiovascular disease, family history of heart attack before 60, or residual cardiovascular events despite statin therapy should have Lp(a) measured. The test is inexpensive (~$25–50 out-of-pocket), needs to be done only once (as levels are genetically set), and identifies a population that requires substantially different management than standard lipid treatment.
TMAO: The Gut-Cardiovascular Axis
Trimethylamine N-oxide (TMAO) is a gut-derived metabolite that directly promotes atherosclerosis by activating macrophage scavenger receptors, impairing reverse cholesterol transport, and promoting platelet reactivity. TMAO is produced when gut bacteria (primarily Prevotella copri, Clostridium hathewayi, and others with CutC/CutD enzyme genes) convert dietary choline, betaine, carnitine, and phosphatidylcholine into TMA — which is then oxidized by hepatic FMO3 (flavin-containing monooxygenase 3) into TMAO.
Tang et al. (2013, Nature Medicine) measured fasting plasma TMAO in 4,007 patients undergoing elective cardiac catheterization, finding that the highest TMAO quartile had 2.54-fold higher risk of major adverse cardiovascular events (MACE) vs the lowest quartile over 3 years — independent of traditional cardiovascular risk factors. The causal role was confirmed: germ-free mice colonized with TMAO-producing bacteria developed accelerated atherosclerosis; antibiotic treatment suppressed TMAO and atherosclerotic plaque formation.
TMAO clinical management: TMAO is elevated by red meat, egg yolks, dairy, and certain fish — all high in choline and carnitine. A Mediterranean diet pattern reduces plasma TMAO vs Western diet. Resveratrol inhibits FMO3 and reduces TMAO 40% in controlled trials (Chen et al., 2016, Scientific Reports). DMB (3,3-Dimethyl-1-butanol) is a specific TMA lyase inhibitor that completely blocks gut TMA production in animal models — human trials are pending. Microbiome modification with specific probiotic strains (Lactobacillus plantarum, which lacks TMA-producing genes) competitively inhibits TMAO-producing bacteria. Plasma TMAO testing is available through Cleveland HeartLab, Boston Heart Diagnostics, and Quest Diagnostics.
Coronary Calcium Score (CAC): The Atherosclerosis Imaging Biomarker
The coronary artery calcium (CAC) score measures the total calcified atherosclerotic plaque burden in the coronary arteries using a low-radiation CT scan (no contrast, no dye, radiation equivalent to approximately 5–10 chest X-rays). Calcium in coronary arteries reflects healed, advanced atherosclerotic plaque — it is direct anatomical evidence of atherosclerotic disease, not merely a risk factor.
CAC Score 0: No detectable plaque. Multiple large studies (MESA, EISNER) show CAC = 0 is associated with a 15-year cardiovascular mortality rate of less than 1% — the “coronary calcium guarantee.” Men and women with CAC = 0 can often safely defer statin therapy. CAC 1–100: Mild plaque burden, moderately elevated risk. CAC 100–400: Significant plaque burden, statin therapy strongly indicated. CAC >400: Extensive plaque burden, high-intensity statin therapy and aggressive risk factor management indicated regardless of other biomarkers.
The MESA study (Detrano et al., 2008, NEJM) followed 6,722 individuals for 3.75 years, finding CAC to be the strongest predictor of coronary heart disease events — independent of and superior to the Framingham Risk Score. Individuals with CAC >300 had a 7.7-fold higher coronary event rate vs those with CAC = 0, despite similar Framingham scores. The 2018 ACC/AHA Cholesterol Guidelines formally incorporated CAC into the decision algorithm for statin initiation in intermediate-risk individuals.
CAC testing is indicated for asymptomatic individuals aged 40–75 with intermediate cardiovascular risk (7.5–20% 10-year risk by pooled cohort equations) in whom the statin therapy decision is uncertain. It is also appropriate for motivated younger individuals (35–45) with family history of premature cardiovascular disease seeking evidence-based risk stratification.
The PREDIMED Trial: Mediterranean Diet Evidence for Cardiovascular Prevention
The PREDIMED trial (Prevención con Dieta Mediterránea; Estruch et al., 2013 and 2018, NEJM) is the most important nutritional cardiovascular intervention trial ever conducted. 7,447 high-risk individuals were randomized to a Mediterranean diet supplemented with extra-virgin olive oil (EVOO, 1L/week), a Mediterranean diet supplemented with mixed nuts (30g/day walnuts, hazelnuts, almonds), or a low-fat control diet. After 4.8 years:
The Mediterranean diet + EVOO group had a 31% relative reduction in major cardiovascular events (MI, stroke, cardiovascular death) vs control. The Mediterranean diet + nuts group had a 28% reduction. These effect sizes are comparable to statin therapy in high-risk populations — produced by diet alone, without caloric restriction or weight loss requirements.
The mechanistic pathways: EVOO polyphenols (hydroxytyrosol, oleocanthal) inhibit LDL oxidation, reduce platelet aggregation, suppress NF-κB inflammatory signaling, and exhibit COX-1/COX-2 inhibitory activity (oleocanthal at 50g EVOO/day is equivalent to 1/10th the anti-inflammatory dose of ibuprofen). Nuts provide magnesium (endothelial protection), L-arginine (eNOS substrate for NO production), and alpha-linolenic acid (ALA, omega-3 precursor). The combination shifts the immune and lipid environment away from the atherogenic phenotype driven by refined oils and processed foods.
The PREDIMED-Plus trial (2020, NEJM) tested a caloric restriction plus Mediterranean diet approach — producing both cardiovascular risk reduction and weight loss — further supporting the Mediterranean dietary pattern as the evidence base for functional cardiovascular prevention.
Endothelial Function: The Root of Cardiovascular Disease
Atherosclerosis begins with endothelial dysfunction — not with lipid deposition. The intact endothelium produces nitric oxide (NO) via endothelial nitric oxide synthase (eNOS), which maintains vasodilation, prevents platelet aggregation, suppresses adhesion molecule expression, and inhibits smooth muscle cell proliferation. When endothelial NO production is impaired (by oxidative stress, hyperglycemia, elevated ApoB, hypertension, or smoking), the endothelium shifts from anti-atherogenic to pro-atherogenic — adhesion molecules (VCAM-1, ICAM-1) recruit monocytes, LDL particles penetrate sub-endothelial space, oxidized LDL (oxLDL) triggers foam cell formation, and the atherosclerotic plaque begins.
The functional assessment of endothelial function includes: flow-mediated dilation (FMD) by brachial ultrasound (gold standard, measures endothelium-dependent vasodilation); digital EndoPAT (fingertip peripheral arterial tonometry, FDA-cleared, measures reactive hyperemia index); and asymmetric dimethylarginine (ADMA) — an endogenous eNOS inhibitor elevated in metabolic syndrome, kidney disease, and cardiovascular disease that directly reflects endothelial NO production capacity.
Evidence-based endothelial function optimization: Omega-3 EPA+DHA (2–4g/day) — Omega-3s reduce ADMA, increase endothelial NO, and reduce F2-isoprostanes (oxidative stress markers). The REDUCE-IT trial (Bhatt 2019, NEJM) showed 4g/day icosapentaenoic acid (EPA-only, Vascepa) reduced MACE by 25% in patients with elevated triglycerides on statin therapy — an effect partly independent of triglyceride reduction. High-dose magnesium (400–600mg/day) — magnesium is a calcium channel antagonist that relaxes vascular smooth muscle and supports eNOS function. L-arginine (3–6g/day) or L-citrulline (3–6g/day, preferred as it sustains plasma arginine longer) provides the eNOS substrate for NO synthesis. Beetroot juice or dietary nitrate (400mg dietary nitrate from 2–3 servings of arugula, spinach, beetroot) provides non-eNOS-dependent NO via the dietary nitrate-nitrite-NO pathway — bypassing endothelial dysfunction to deliver NO directly to the vasculature.
Advanced Cardiovascular Risk Assessment: The Complete Panel
A complete functional cardiovascular risk panel for patients at intermediate or high risk includes:
Lipid and lipoprotein markers: ApoB (target <80 mg/dL high-risk, <100 mg/dL general prevention); Lp(a) (single lifetime measurement, target below 30 mg/dL); LDL particle number (NMR LipoProfile, measures small dense LDL proportion); sdLDL-C (small dense LDL cholesterol, elevated in metabolic syndrome); triglycerides (target <100 mg/dL fasting, below 150 non-fasting); non-HDL cholesterol (ApoB surrogate when ApoB unavailable: all cholesterol except HDL, target <130 mg/dL general, <100 mg/dL high-risk).
Inflammatory and oxidative markers: hs-CRP (target <1.0 mg/L; JUPITER trial showed rosuvastatin 20mg in elevated hs-CRP patients with low LDL reduced MACE 44%); Lp-PLA2 (lipoprotein-associated phospholipase A2, a marker of vulnerable plaque activity, target <200 ng/mL); oxidized LDL (oxLDL, directly measures atherogenic oxidative modification of LDL, target <70 U/L); homocysteine (target <7 μmol/L; elevated homocysteine is an independent MACE risk factor and responds to methylfolate + B12 supplementation).
Metabolic markers: Fasting insulin (target <5 μU/mL); HOMA-IR (target <1.0); HbA1c (target <5.4%); uric acid (target <5.0 mg/dL; hyperuricemia independently predicts cardiovascular events via endothelial dysfunction and inflammation); TMAO (cardiovascular risk, discussed above).
Imaging: CAC score (described above); carotid intima-media thickness (CIMT) — the subclinical atherosclerosis progression marker used in ELITE, CIMT above 0.9 mm indicates advanced subclinical disease; Ankle-Brachial Index (ABI) — peripheral arterial disease screening, ABI <0.9 indicates significant peripheral atherosclerosis.
Frequently Asked Questions
Is ApoB better than LDL for predicting heart disease?
Yes — across multiple large prospective studies and Mendelian randomization analyses, ApoB outperforms LDL-C for cardiovascular risk prediction, particularly in individuals with metabolic syndrome, insulin resistance, or elevated triglycerides (who may have high LDL particle numbers despite “normal” LDL-C). The 2022 European Society of Cardiology guidelines designate ApoB as the preferred lipid risk marker for primary prevention decision-making.
What is Lp(a) and should I be tested for it?
Lp(a) is a genetically determined lipoprotein particle that is an independent cardiovascular risk factor. Elevated Lp(a) (>50 mg/dL or >125 nmol/L) affects approximately 20% of people. You should be tested if you have: a family history of premature coronary artery disease, unexplained early heart attack or stroke, residual cardiovascular events despite statin therapy, or want a complete cardiovascular risk assessment. The test needs to be done only once as levels are genetically determined. No lifestyle changes significantly reduce Lp(a) — new RNA-targeted therapies (pelacarsen, olpasiran) are in phase III trials.
Does the PREDIMED diet include red meat?
The PREDIMED Mediterranean diet pattern includes abundant olive oil, vegetables, fruits, legumes, nuts, whole grains, and fish; moderate poultry; limited red and processed meat (less than once weekly); and moderate wine (with meals if consumed). The EVOO supplementation arm used 1 liter of extra-virgin olive oil per week for the household. The primary restriction was processed foods, refined oils (especially trans fats, the version used in the 1990s control diet), and processed meats — not total animal protein.
What is a healthy triglyceride level?
Lab “normal” is below 150 mg/dL, but functional medicine targets below 100 mg/dL fasting — ideally below 80 mg/dL — as elevated triglycerides reflect excess carbohydrate intake, insulin resistance, and elevated VLDL particle number. Triglyceride-to-HDL ratio is a useful insulin resistance surrogate: >3.0 strongly predicts small dense LDL dominance; <1.5 indicates predominantly large buoyant LDL. High-dose omega-3 (icosapentaenoic acid + docosahexaenoic acid, 3–4g/day), dietary carbohydrate reduction, and metabolic normalization are the most effective interventions for elevated triglycerides.
What does a coronary calcium score of zero mean?
A CAC score of 0 means no detectable calcified atherosclerotic plaque in the coronary arteries. Multiple large studies (MESA, EISNER) show that CAC = 0 is associated with a <1% 15-year cardiovascular mortality rate — the “calcium guarantee.” For asymptomatic individuals with intermediate risk factors, a CAC of 0 suggests that statin therapy may be safely deferred and motivates lifestyle optimization as primary prevention. CAC should be reassessed every 5–10 years or when clinical status changes.
Functional cardiology is not just about knowing your LDL number — it is about understanding the complete atherogenic risk profile and deploying the interventions that address ApoB, Lp(a), endothelial function, TMAO, and inflammation simultaneously. If you want a comprehensive functional cardiovascular risk assessment that goes beyond the standard lipid panel, contact our office at (810) 206-1402.